Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) SVP Laurie Keating sold 20,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $145.00, for a total value of $2,900,000.00. Following the transaction, the senior vice president now directly owns 24,500 shares in the company, valued at $3,552,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Laurie Keating also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Wednesday, December 20th, Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $121.20, for a total value of $757,378.80.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded down $2.33 on Wednesday, hitting $141.83. The stock had a trading volume of 1,001,373 shares, compared to its average volume of 751,388. The stock has a market cap of $13,950.00, a PE ratio of -26.22 and a beta of 2.67. Alnylam Pharmaceuticals, Inc. has a twelve month low of $46.90 and a twelve month high of $152.75. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). The firm had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The firm’s revenue was up 116.6% on a year-over-year basis. During the same period last year, the company earned ($1.32) earnings per share. analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.88 earnings per share for the current year.

A number of research analysts have recently weighed in on ALNY shares. BidaskClub raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. Credit Suisse Group boosted their price target on Alnylam Pharmaceuticals from $151.00 to $154.00 and gave the stock an “outperform” rating in a report on Tuesday. B. Riley reissued a “buy” rating and issued a $205.00 price target (down from $220.00) on shares of Alnylam Pharmaceuticals in a report on Monday, January 8th. Jefferies Group set a $156.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 9th. Finally, Leerink Swann boosted their price target on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a report on Thursday, January 25th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average target price of $126.89.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 16.4% during the 4th quarter. BlackRock Inc. now owns 7,115,063 shares of the biopharmaceutical company’s stock worth $903,969,000 after acquiring an additional 1,003,366 shares in the last quarter. UBS Asset Management Americas Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 2.2% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,394,213 shares of the biopharmaceutical company’s stock worth $177,135,000 after acquiring an additional 29,816 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Alnylam Pharmaceuticals by 8.6% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 1,217,367 shares of the biopharmaceutical company’s stock worth $154,666,000 after acquiring an additional 96,812 shares in the last quarter. Orbimed Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 69.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after acquiring an additional 445,600 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 13.4% during the 4th quarter. Geode Capital Management LLC now owns 747,646 shares of the biopharmaceutical company’s stock worth $94,929,000 after acquiring an additional 88,119 shares in the last quarter. 92.44% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/insider-selling-alnylam-pharmaceuticals-inc-alny-svp-sells-20000-shares-of-stock.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.